The White House threw its weight behind efforts to help US biotech compete with China, using the administration’s budget proposal to outline FDA policy changes

Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown

Plus: Debt financing deals for Apnimed and Opus Genetics Anthropic buys a stealth biotech: The San Francisco artificial intelligence giant is buying Coefficient Bio, building

In response to a warning letter from the FDA that accused the company of making “false or misleading” claims about its bladder cancer drug Anktiva,

Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share,